Literature DB >> 23326117

Carcinoma of the gastroesophageal junction in Chinese patients.

Qin Huang1.   

Abstract

Carcinoma of the gastroesophageal junction (GEJ) is defined as carcinoma that crosses the GEJ line, irrespective of where the tumor epicenter is located. This group of cancer is rare but controversial. Based on study results from the majority of epidemiologic and clinicopathologic investigations carried out in Western countries, this cancer is believed to arise from Barrett's esophagus (BE) and includes both distal esophageal and proximal gastric carcinomas because of similar characteristics in epidemiology, clinicopathology, and molecular pathobiology in relation to BE. As such, the most recent American Joint Committee on Cancer staging manual requires staging all GEJ carcinomas with the rule for esophageal adenocarcinoma (EA). This mandate has been challenged recently by the data from several studies carried out mainly in Chinese patients. The emerging evidence derived from those studies suggests: (1) both BE and EA are uncommon in the Chinese population; (2) almost all GEJ cancers in Chinese arise in the proximal stomach and show the features of proximal gastric cancer, not those of EA; (3) application of the new cancer staging rule to GEJ cancer of Chinese patients cannot stratify patients' prognosis effectively; and (4) prognostic factors of GEJ cancer in Chinese are similar, but not identical, to those of EA. In conclusion, the recent evidence suggests that GEJ cancer in Chinese shows distinct clinicopathologic characteristics that are different from EA. Further investigations in molecular pathology may help illustrate the underlying pathogenesis mechanisms of this cancer in Chinese patients and better manage patients with this fatal disease.

Entities:  

Keywords:  Barrett’s esophagus; Cancer; Esophagus; Gastroesophageal junction; Staging; Stomach

Mesh:

Substances:

Year:  2012        PMID: 23326117      PMCID: PMC3544014          DOI: 10.3748/wjg.v18.i48.7134

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  93 in total

1.  Adenocarcinomas of the distal esophagus and "gastric cardia" are predominantly esophageal carcinomas.

Authors:  Parakrama Chandrasoma; Kumari Wickramasinghe; Yanling Ma; Tom DeMeester
Journal:  Am J Surg Pathol       Date:  2007-04       Impact factor: 6.394

Review 2.  Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction.

Authors:  W A Marsman; G N J Tytgat; F J W ten Kate; J J B van Lanschot
Journal:  J Surg Oncol       Date:  2005-12-01       Impact factor: 3.454

3.  Risk stratification for early esophageal adenocarcinoma: analysis of lymphatic spread and prognostic factors.

Authors:  Andrew P Barbour; Mark Jones; Ian Brown; David C Gotley; Ian Martin; Janine Thomas; Andrew Clouston; B Mark Smithers
Journal:  Ann Surg Oncol       Date:  2010-03-27       Impact factor: 5.344

Review 4.  Barrett's esophagus-related diseases remain uncommon in China.

Authors:  Qin Huang; Dian Chun Fang; Cheng Gong Yu; Jun Zhang; Min Hu Chen
Journal:  J Dig Dis       Date:  2011-12       Impact factor: 2.325

Review 5.  Carcinoma of the cardia: classification as esophageal or gastric cancer?

Authors:  Burkhard H A von Rahden; Marcus Feith; Hubert J Stein
Journal:  Int J Colorectal Dis       Date:  2004-10-26       Impact factor: 2.571

6.  Aetiology and classification of adenocarcinoma of the gastro-oesophageal junction/cardia.

Authors:  Kenneth E L McColl; James J Going
Journal:  Gut       Date:  2010-03       Impact factor: 23.059

7.  The prognostic importance of pathologically involved celiac node metastases in node-positive patients with carcinoma of the distal esophagus or gastroesophageal junction: a surgical series from the Mayo Clinic.

Authors:  David A Schomas; J Fernando Quevedo; James M Donahue; Francis C Nichols; Yvonne Romero; Robert C Miller
Journal:  Dis Esophagus       Date:  2009-06-09       Impact factor: 3.429

8.  Clinical, epidemiologic, and morphologic comparison between adenocarcinomas arising in Barrett's esophageal mucosa and in the gastric cardia.

Authors:  R J Kalish; P E Clancy; M B Orringer; H D Appelman
Journal:  Gastroenterology       Date:  1984-03       Impact factor: 22.682

Review 9.  Barrett's esophagus, dysplasia, and adenocarcinoma.

Authors:  R C Haggitt
Journal:  Hum Pathol       Date:  1994-10       Impact factor: 3.466

10.  Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China.

Authors:  F Kamangar; Y-L Qiao; M J Blaser; X-D Sun; H Katki; J-H Fan; G I Perez-Perez; C C Abnet; P Zhao; S D Mark; P R Taylor; S M Dawsey
Journal:  Br J Cancer       Date:  2006-12-19       Impact factor: 7.640

View more
  6 in total

1.  Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconstruction after gastrectomy for Siewert types II and III adenocarcinoma of the esophagogastric junction.

Authors:  Jiang-Wei Xiao; Zi-Lin Liu; Peng-Cheng Ye; Ya-Jun Luo; Zhi-Ming Fu; Qin Zou; Shou-Jiang Wei
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

Review 2.  Obesity and related risk factors in gastric cardia adenocarcinoma.

Authors:  Sidney Olefson; Steven F Moss
Journal:  Gastric Cancer       Date:  2014-09-11       Impact factor: 7.370

3.  SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma.

Authors:  Li-Ying OuYang; Zi-Jian Deng; Yu-Feng You; Jia-Ming Fang; Xi-Jie Chen; Jun-Jie Liu; Xian-Zhe Li; Lei Lian; Shi Chen
Journal:  Front Immunol       Date:  2022-08-16       Impact factor: 8.786

4.  Dual-layer dual-energy CT for improving differential diagnosis of squamous cell carcinoma from adenocarcinoma at gastroesophageal junction.

Authors:  Meihong Wu; Mao Sheng; Ruomei Li; Xinna Zhang; Xingbiao Chen; Yin Liu; Bin Liu; Yongqiang Yu; Xiaohu Li
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

5.  Application of computed tomography-based radiomics in differential diagnosis of adenocarcinoma and squamous cell carcinoma at the esophagogastric junction.

Authors:  Ke-Pu Du; Wen-Peng Huang; Si-Yun Liu; Yun-Jin Chen; Li-Ming Li; Xiao-Nan Liu; Yi-Jing Han; Yue Zhou; Chen-Chen Liu; Jian-Bo Gao
Journal:  World J Gastroenterol       Date:  2022-08-21       Impact factor: 5.374

6.  Golgi scaffold protein PAQR3 as a candidate suppressor of gastric cardia adenocarcinoma via regulating TGF-β/Smad pathway.

Authors:  Ying-Li Wu; Lian-Lian Hong; Zhe-Nan Ling; Xuan-Yu Hu; Zhu Liu; Pei Li; Zhi-Qiang Ling
Journal:  J Clin Lab Anal       Date:  2022-07-23       Impact factor: 3.124

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.